51 | Add to Reading ListSource URL: www.naspghan.orgLanguage: English - Date: 2014-06-19 13:27:40
|
|---|
52 | Add to Reading ListSource URL: www.naspghan.orgLanguage: English - Date: 2014-06-17 13:40:18
|
|---|
53![REMS Initial REMS Approval: [removed]Most Recent Modification: [removed]NDA 203,214 XELJANZ® (TOFACITINIB)](https://www.pdfsearch.io/img/c0fdfdef62910c137419a6a885bb7409.jpg "REMS Initial REMS Approval: [removed]Most Recent Modification: [removed]NDA 203,214 XELJANZ® (TOFACITINIB)") | Add to Reading ListSource URL: www.fda.govLanguage: English |
|---|
54 | Add to Reading ListSource URL: www.nhhealthyfamilies.comLanguage: English - Date: 2013-12-04 21:16:01
|
|---|
55![IARC MONOGRAPHS SUPPLEMENT[removed]Group 2 trial process or occupational exposure is](https://www.pdfsearch.io/img/b44c5e8c787c22416395ed6d15025373.jpg "IARC MONOGRAPHS SUPPLEMENT[removed]Group 2 trial process or occupational exposure is") | Add to Reading ListSource URL: monographs.iarc.frLanguage: English - Date: 2012-08-13 12:55:21
|
|---|
56 | Add to Reading ListSource URL: www.mipedscompounds.orgLanguage: English - Date: 2014-01-23 23:01:15
|
|---|
57 | Add to Reading ListSource URL: www.tritonpharma.caLanguage: English - Date: 2011-11-08 15:24:38
|
|---|
58 | Add to Reading ListSource URL: www.in.govLanguage: English - Date: 2014-10-01 18:09:09
|
|---|
59 | Add to Reading ListSource URL: www.tritonpharma.caLanguage: English - Date: 2011-11-08 15:24:38
|
|---|
60 | Add to Reading ListSource URL: www.tritonpharma.caLanguage: English - Date: 2011-11-08 15:24:38
|
|---|